Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2013; 109(02): 272-279
DOI: 10.1160/TH12-09-0658
DOI: 10.1160/TH12-09-0658
Platelets and Blood Cells
Prevalence of thrombocytosis in critically ill patients and its association with symptomatic acute pulmonary embolism
A multicentre registry studyFurther Information
Publication History
Received:
08 September 2012
Accepted after major revision:
09 November 2012
Publication Date:
29 November 2017 (online)
Summary
It is uncertain whether thrombocytosis without underlying myeloproliferative diseases is associated with an increased risk of acute pulmonary embolism (PE). We investigated the relationship between thrombocytosis and risk of symptomatic acute PE, and whether Pulmonary Embolism Severity Index (PESI) was reliable in predicting mortality of acute PE. This multicentre registry study involved a total of 609,367 critically ill patients admitted to 160 intensive care units (ICUs) in Australia or New Zealand between 2006 and 2011. Forward stepwise logistic regression was used to assess the relationship between risk of acute PE and platelet counts on intensive care unit (ICU) admission. Acute PE (n=3387) accounted for 0.9% of all emergency ICU admissions. Over 20% of all PE required mechanical ventilation, 4.2% had cardiac arrest, and the mortality was high (14.8%). Thrombocytosis, defined by a platelet count >500×109 per litre, occurred in 2.1% of the patients and was more common in patients with acute PE than other diagnoses (3.4 vs. 2.0%). The platelet counts explained about 4.5% of the variability and had a linear relationship with the risk of acute PE (odds ratio 1.19 per 100×109 per litre increment in platelet count, 95% confidence interval 1.06–1.34), after adjusting for other covariates. The PESI had a reasonable discriminative ability (area under receiver-operating-characteristic curve = 0.78) and calibration to predict mortality across a wide range of severity of acute PE. In summary, thrombocytosis was associated with an increased risk of symptomatic acute PE. PESI was useful in predicting mortality across a wide range of severity of acute PE.
-
References
- 1 Galson SK. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Available at: http://www.surgeongeneral.gov/topics/deepvein/. Accessed July 12, 2012.
- 2 National Quality Forum.. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: additional performance measures. Executive summary 2008. Available at: http://www.qualityforum.org/Publications/2008/10/National_Voluntary_Consensus_Standards_for_Prevention_and_Care_of_Venous_Thromboembolism__Additional_Performance_Measures.aspx. Accessed July 15, 2012.
- 3 Beckman MG, Hooper WC, Critchley SE. et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38: S495-501.
- 4 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-1846.
- 5 Schafer AI. Thrombocytosis. N Engl J Med 2004; 350: 1211-1219.
- 6 Buss DH, Cashell AW, O’Connor ML. et al. Occurrence, etiology and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96: 247-253.
- 7 Duff O, Ho KM, Maybury SM. In-vitro thrombotic tendency of reactive thrombocytosis in critically ill patients: a prospective case-control study. Anaesth Intensive Care 2012; 40: 472-478.
- 8 Salim A, Hadjizacharia P, DuBose J. et al. What is the significance of thrombocytosis in patients with trauma?. J Trauma 2009; 66: 1349-1354.
- 9 Kashuk JL, Moore EE, Johnson JL. et al. Progressive postinjury thrombocytosis is associated with thromboembolic complications. Surgery 2010; 148: 667-675.
- 10 Schmuziger M, Christenson JT, Maurice J. et al. Reactive thrombocytosis after coronary bypass surgery. An important risk factor. Eur J Cardiothorac Surg 1995; 09: 393-398.
- 11 Lancaster RT, Conrad MF, Patel VI. et al. Predictors of Early Graft Failure After Infrainguinal Bypass Surgery: A Risk-adjusted Analysis from the NSQIP. Eur J Vasc Endovasc Surg 2012; 43: 549-555.
- 12 Tchebiner JZ, Nutman A, Boursi B. et al. Diagnostic and prognostic value of thrombocytosis in admitted medical patients. Am J Med Sci 2011; 342: 395-401.
- 13 Vidwan P, Lee S, Rossi JS. et al. Relation of platelet count to bleeding and vascular complications in patients undergoing coronary angiography. Am J Cardiol 2010; 105: 1219-1222.
- 14 Iijima R, Ndrepepa G, Mehilli J. et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemost 2007; 98: 852-857.
- 15 Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10: 1768-1774.
- 16 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-1302.
- 17 Becattini C, Agnelli G, Schenone A. et al. WARFASA Investigators.. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.
- 18 Aujesky D, Obrosky DS, Stone RA. et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-1046.
- 19 Australian and New Zealand Intensive Care Society: Database Management Committee.. Available at: http://www.anzics.com.au/article.asp?Section=dmg&ID=31 Accessed December 15, 2010.
- 20 Ho KM, Knuiman M, Finn J. et al. Estimating long-term survival of critically ill patients: the PREDICT model. PLoS One 2008; 03: e3226.
- 21 Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost 2010; 08: 1509-1514.
- 22 Simanek R, Vormittag R, Ay C. et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 08: 114-120.
- 23 Gulcan M, Varol E, Etli M. et al. Mean platelet volume is increased in patients with deep vein thrombosis. Clin Appl Thromb Hemost 2012; 18: 427-430.
- 24 Yoshida S, Kohro S, Yamakage M. et al. A case of suspected pulmonary thrombosis in a patient with reactive thrombocytemia who underwent liver subsegmentectomy. Masui 2003; 52: 1320-1322.
- 25 Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2012; 21: 27-31.
- 26 Lang IM, Pesavento R, Bonderman D. et al. Risk factors and basic mechanisms of CTEPH - a current understanding. Eur Respir J. 2012 Epub ahead of print.
- 27 Stamous KM, Toutouzas KG, Kekis PB. et al. Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins. Arch Surg 2006; 141: 663-669.
- 28 Peerschke EI, Silver RT, Weksler BB. et al. Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. Am J Clin Pathol 2007; 127: 422-428.
- 29 Cohen AT. The burden of venous thromboembolism in the hospital setting. Pathophysiol Haemost Thromb 2009; 37: 102.
- 30 Ho KM, Burrell M, Rao S. et al. Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010; 105: 596-602.
- 31 Cohen AT, Tapson VF, Bergmann JF. et al. ENDORSE Investigators.. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394.
- 32 Cohen AT. Prevention of postoperative venous thromboembolism. Br Med J 2009; 339: b4477.
- 33 Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011; 140: 1436-1446.
- 34 Liu DS, Lee MM, Spelman T. et al. Medication chart intervention improves inpatient thromboembolism prophylaxis. Chest 2012; 141: 632-641.
- 35 Nendaz MR, Chopard P, Lovis C. et al. Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems. J Thromb Haemost 2010; 08: 1230-1234.
- 36 Goldhaber SZ. Eradication of hospital-acquired venous thromboembolism. Thromb Haemost 2010; 104: 1089-1092.
- 37 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969-977.
- 38 Ho KM, Litton E. Venous thromboembolism prophylaxis in hospitalized elderly patients: Time to consider a 'MUST' strategy. J Geriatr Cardiol 2011; 08: 114-120.
- 39 Bonderman D, Jakowitsch J, Adlbrecht C. et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512-516.
- 40 Rosenbaum PR. Does a dose-response relationship reduce sensitivity to hidden bias?. Biostatistics 2003; 04: 1-10.
- 41 Rinder HM, Schuster JE, Rinder CS. et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91: 1288-1294.